07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) IL-4 (BSF1); fibronectin extra domain A (FnEDA) Mouse studies suggest an antibody-IL-4 fusion protein could help treat RA. In mouse models...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Scleroderma Toll-like receptor 4 (TLR4); fibronectin extra domain A (FnEDA) In vitro and mouse studies suggest inhibiting TLR4 signaling in skin lesions could help...
07:00 , May 8, 2014 |  BC Innovations  |  Targets & Mechanisms

TLR4 on the surface of scleroderma

BioLineRx Ltd. 's deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma. 1 It is still unclear whether the university's toll-like receptor...
07:00 , Apr 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD40; toll-like receptor 3 (TLR3); TLR4 Studies in mice suggest that combining multiple adjuvants and antigen-targeting compounds could help treat tumors with low immunogenicity....